Dogwood Therapeutics Q3 net loss narrows 69% to $4.88 million
DWTX•Dogwood Therapeutics’ third-quarter net loss narrowed 69% year over year to $4.88 million, while revenue rose to $100,000 and research and development expenses fell 77% to $3.35 million. The 239-patient Halneuron Phase 2b trial is complete, with top-line results expected in November 2026; a $5 million private placement and existing cash provide runway through the first quarter of 2027.
1. Quarterly results and trial update
Dogwood Therapeutics reported a third-quarter 2026 net loss attributable to common stockholders of $4.88 million, down 69% year over year. Revenue rose to $100,000, and research and development expenses fell 77% to $3.35 million. The Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain finished with 239 patients enrolled, and top-line results are expected in November 2026. A $5 million private placement with Sealbond Limited, together with existing cash, provides operational runway through the first quarter of 2027.
